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ABSTRACT 
 
Objectives: To update the 1997 OMERACT-OARSI Core Domain Set for clinical trials in hip and/or knee 
osteoarthritis (OA).  
Methods: An initial review of the COMET database of core outcome sets (COS) was undertaken to 
identify all domains reported in previous COS including individuals with hip and/or knee OA. These 
were presented during five patient and health professionals/researcher meetings in three continents 
(Europe, Australasia, North America). A three-round international Delphi survey was then undertaken 
among patients, healthcare professionals, researchers and industry representatives to gain consensus 
on key domains to be included in a core domain set for hip and/or knee OA. Findings were presented 
and discussed in small groups at OMERACT2018 where consensus was obtained in the final plenary. 
Results: Four previous COS were identified. Using these, and the stakeholder meetings, 50 potential 
domains formed the Delphi survey. 426 individuals from 25 different countries contributed to the 
Delphi exercise. OMERACT2018 delegates (N=129) voted on candidate domains. Six domains gained 
agreement as mandatory to be measured and reported in all hip and/or knee OA clinical trials ? ‘ƉĂŝŶ ? ?
 ‘ƉŚǇƐŝĐĂůĨƵŶĐƚŝŽŶ ? ? ‘ƋƵĂůŝƚǇŽĨůŝĨĞ ?ĂŶĚ ‘ƉĂƚŝĞŶƚŐůŽďĂůĂƐƐĞƐƐŵĞŶƚŽĨƚŚĞƚĂƌŐĞƚũŽŝŶƚ ?ŝŶĂĚĚŝƚŝŽŶƚŽƚŚĞ
mandated core domain ŽĨ  ‘ĂĚǀĞƌƐĞ ĞǀĞŶƚƐ ŝŶĐůƵĚŝŶŐ ŵŽƌƚĂůŝƚǇ ? ? ‘:ŽŝŶƚ ƐƚƌƵĐƚƵƌĞ ? ǁĂƐ ĂŐƌĞĞĚ ĂƐ
mandatory in specific circumstances, stating the specific circumstances, i.e. depending on the 
intervention. 
Conclusions: The updated core domain set for hip and/or knee OA has been agreed upon. Work will 
commence to determine which outcome measurement instrument should be recommended to cover 
each core domain. 
 
Keywords: Osteoarthritis; Hip Joint; Knee Joint; OMERACT; Outcome Measure; Clinical Trials 
 
Word Count: Abstract: 250; Main Paper: 2973 
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INTRODUCTION 
 
Osteoarthritis (OA) is one of the most common musculoskeletal diseases, with an estimated 
prevalence of 12% to 22% worldwide.(1) It is the leading cause of disability amongst older adults, with 
an estimated lifetime risk of knee OA being approximately 40% in men and 47% in females.(2) The 
most common symptoms associated with OA are pain, stiffness and fatigue, associated with disability 
and loss of physical activity and functional independence.(1,2)  
 
Clinical trials seek to determine whether treatments are safe and beneficial for patients by comparing 
their relative effects on outcomes chosen to identify benefit or harm.(3) The results can then be used 
to make decisions on whether a treatment under-investigation should be recommended or not. It is 
therefore essential that outcomes reported in trials are those which are needed by decision-makers, 
and reflect meaningful measures for patients, clinicians and other stakeholders.(4,5)  
 
The OMERACT group was established in 1992 with the aim of bringing together people interested in 
the development, reporting and application of core outcome sets (COS). A COS is an agreed set of 
outcomes (domains) which clinical trialists should measure and report in all clinical trials of a specific 
condition.(6,7) A COS also includes recommendations on what outcome measurement instrument 
should be used to measure these core domains.(6,7) Thus, a COS ĐŽŶƐŝƐƚƐ ŽĨ  ‘ĚŽŵĂŝŶƐ ? ĂŶĚ
 ‘ŝŶƐƚƌƵŵĞŶƚƐ ? ? 
 
There are four core areas that should be covered in an OMERACT core domain set with at least one 
domain in each of the areas: death, life impact, and pathophysiological manifestations; and one 
strongly recommended: resource use (if resource use will not be included, there needs to be an 
adequate and agreed upon justification for its exclusion).(6) All COS should also consider factors which 
are not the primary object of research but that may influence the results or the interpretation of the 
results.(6) These are known as contextual factors.(6) An instrument is the outcome measurement 
instrument which is recommended to measure that specific domain, e.g. questionnaires to assess 
quality of life, scales to assess cost, instruments to measure of body function and tests and imaging to 
assess biomarkers. The key principles for selecting core domains and corresponding instruments are 
international consultation between patients, health professionals, researchers and industry followed 
by consensus.(6-8) Through this, any consensus achieved by an OMERACT working group is perceived 
as being informed through key stakeholder opinion, and to have a worldwide perspective. 
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In 1997 OMERACT in conjunction with the Osteoarthritis Research Society International (OARSI) 
developed a COS hip and knee OA,(9) comprising four core domains to be measured and reported in 
all hip and knee OA clinical trials: pain; physical function; patient global assessment; and for studies 
with a follow-up period of a year or longer, joint imaging (such as x-ray). Over the past 20 years, there 
have been developments in how the OMERACT COS are developed, with greater emphasis on patient 
involvement.(6,10,11) Furthermore, there have been developments in how domains are identified 
through the recent adoption of the OMERACT Filter 2.0.(6) These guidelines were not established 
when Bellamy et al(9) developed their COS for hip/knee OA in 1997. 
 
Given developments in methodology, the OMERACT group agreed that the previous hip and knee OA 
COS should be reviewed. The purpose of this work was therefore to undertake this. To do this, this 
project was divided into three phases: review of current COS for patients with hip and knee OA (phase 
1); Delphi exercise to establish worldwide perspectives on what are potential domains of interest 
(phase 2); and OMERACT2018 meeting to establish consensus and the update core domain set (phase 
3). 
 
This paper reports these phases and presents the OMERACT-OARSI core domain set to measure in 
clinical trials for people with hip and/or knee OA. 
 
METHODS AND RESULTS 
 
Research ethics approval was gained ĨƌŽŵƚŚĞhŶŝǀĞƌƐŝƚǇŽĨĂƐƚŶŐůŝĂ ?Ɛ ?hŶŝƚĞĚ<ŝŶŐĚŽŵ ?&ĂĐƵůƚǇŽĨ
Medicine and Health Sciences Research Ethics Committee on 14th September 2017 (Ref: 2016/2017-
104). 
 
Phase 1 
 
All COS that included the views of people with hip or knee OA were reviewed from the COMET (Core 
Outcome Measures in Effectiveness Trials) database, a repository of published and ongoing COS 
projects.(12) From 218 COS in musculoskeletal diseases, four COS where identified which included the 
views of people with hip or knee OA.(8,13-15)  
 
Five patient and health professional/researcher meetings were held to pilot the list of candidate 
domains, based on the results of the review of the COMET COS, prior to the Delphi project. These 
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were conducted across three countries (Canada (Toronto), Australia (Sydney) and the UK (Leeds and 
Norwich)) involving 35 people with hip and/or knee OA, 34 healthcare professionals and one non-
clinical researcher. The role of these groups was to determine whether any candidate domains were 
missing, whether some domains were repetitious and required merging or whether the Delphi Round 
1 survey wording was ambiguous. Amendments were made in accordance with these 
recommendations before launching the Delphi exercise.  
 
Phase 2 
 
Participants and Sample Size 
The study flow is illustrated in Figure 1. The target population was people with hip and knee OA, and 
professionals working in areas of relevance to OA, such as healthcare professionals with an interest in 
OA (e.g., nurses, occupational therapists, orthopaedic surgeons, physiotherapists, rheumatologists), 
researchers and people working in the pharmaceutical or device industry (e.g. knee braces and 
orthoses). 
 
There is no consensus on the optimal sample size for a Delphi study.(16) Therefore recruitment was 
based on time-scale. Round 1 was opened for six weeks (19th December 2017 to 27th January 2018) 
using a broad sampling strategy to gain as large a sample as was feasible within the study time-frames. 
 
Distribution and Approach  
The Delphi survey was distributed through a number of streams to ensure broad coverage to the 
target population. These included distributing the survey to members of the Osteoarthritis Research 
Society International (OARSI) members, UK Arthritis Research UK (ARUK) Osteoarthritis Clinical Study 
Group, recipients of the ARUK e-bulletin, members of the Spanish Society of Rheumatology (SER), the 
Italian Rheumatology Society (SIR), the European League Against Rheumatism (EULAR) People With 
Arthritis/Rheumatism (PARE) ? ƉĂƚŝĞŶƚ ƌĞƉƌĞƐĞŶƚĂƚŝǀĞƐ ƚŚƌŽƵŐŚ ƚŚĞ ƌƚŚƌŝƚŝƐ &ŽƵŶĚĂƚŝŽŶ ?Ɛ ĞŵĂŝů
circulate, AustƌĂůŝĂŶ ‘myjointpain ?ŐƌŽƵƉĂŶĚĚĞůĞŐĂƚĞƐƚŽƚŚĞAustralian OA Summit. There were no 
restrictions on who from these groups could contribute. In addition, a social media campaign was 
designed through Twitter to gain further international representation of patient, clinical, research and 
industry representations.  
 
A window of six weeks was allotted to recruit all potential respondents for Round 1 of the Delphi 
exercise. A reminder was sent after three weeks. After the six-week recruitment campaign, the 
8 
 
hyperlink for Round 1 was closed. Round 2 was undertaken from 5th February 2018 to 26th February 
2018, whilst Round 3 was completed from 5th March 2018 to 25th March 2018. 
 
Process 
The Delphi survey was administered via the online software DelphiManager.(17) The DelphiManager 
programme was presented in English and Italian for the PARE and the Italian Rheumatology Society. 
 
Participants were asked to judge the importance of 50 potential core domains, generated from Phase 
1, ďǇĂŶƐǁĞƌŝŶŐ ƚŚĞƋƵĞƐƚŝŽŶ  ‘ŚŽǁ ŝŵƉŽƌtant are the following items to be assessed in trials with 
people with hip and knee OA ? ?As adopted previously,(18) responses were measured where 1-3 
represented  ‘ŶŽƚƚŚĂƚŝŵƉŽƌƚĂŶƚ ? ? ?- ? ‘ŝŵƉŽƌƚĂŶƚ ? ? ?- ‘ĐƌŝƚŝĐĂůůǇŝŵƉŽƌƚĂŶƚ ? ?dŚĞƌĞwaƐĂůƐŽĂŶ ‘Ƶnable 
tŽƐĐŽƌĞ ?option. We provided an open question where participants could indicate if there were any 
further domains which should be assessed but was not in the pre-defined list. Where such a response 
was reported, this was added to Round 2. Participants were also asked whether certain domains 
should be merged because of perceived overlap, i.e. pain intensity (overall) versus pain intensity (at 
rest) or pain intensity (with activity). 
 
In agreement with MacLennan et al(19) approach, domains were excluded in Round 2 if they were 
rated as  ‘ŶŽƚƚŚĂƚŝŵƉŽƌƚĂŶƚ ? ?d3 points) by t15% of one or more stakeholder groups OR included if 
they were rated as  ‘ŝŵƉŽƌƚĂŶƚ ? ?t4 points) by d70% of one or more stakeholder groups. If there was 
agreement from at least 70% of each stakeholder group for a merger of domains, this was performed 
and included in Round 2 domains. 
 
The Round 2 and Round 3 surveys followed the same format, asking the same questions as Round 1, 
adopting the same scoring system and approach to domain reduction and merger. Round 2 and 3 
participants were provided with the mean responses for each domain from the previous round, 
presented by stakeholder group (i.e. patients, healthcare professionals, researchers, industry). 
 
Data Analysis 
The analysis determined which domains were considered most important to be assessed in future 
trials of people with hip and knee OA. For this, descriptive statistics and frequency distributions were 
used to collectively assess all completed Delphi surveys for each of the three Delphi rounds. The data 
were presented as frequency distributions and mean values with standard deviations where 
appropriate. Data were analysed by two groups to inform the OMERACT-OARSI core domain set: 
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 ‘ƉĞŽƉůĞǁŝƚŚOA ?ǀƐ  ‘ŽƚŚĞƌƐƚĂŬĞŚŽůĚĞƌŐƌŽƵƉƐ ? ? Data analyses were performed using the Statistical 
Package for the Social Sciences (SPSS) version 25.0 (SPSS Inc, Chicago, Illinois).  
 
Formation of the Core Domain Set 
The individual item responses provided from the Delphi survey were reviewed and categorised by 
members of the Working Group under overarching domains. This respected the recommendations 
made in Filter 2.1.(7) and OMERACT.(19) Based on these domains, the rules for inclusion of domains 
were: 
 
x Mandatory (Core) Domains: domains which were considered ĂƐ ‘ĐƌŝƚŝĐĂů ?ďǇŽǀĞƌ ? ?A?ŽĨ both 
stakeholder groups (patients AND others); 
x Important but Optional Domains: domains which were considered ĂƐ ‘ĐƌŝƚŝĐĂů ?ďǇŽǀĞƌ ? ?A?ŽĨ 
one stakeholder group (either patients OR others) but not both; 
x Research Agenda: domains which need further research. 
 
Adverse events including mortality/survival were included per default as a core domain as per Filter 
2.1.(7) 
 
In response to discussions at OMERACT 2018, the OMERACT Onion was adjusted and approved. The 
OMERACT onion is a schema which illustrates all three constitutes of core domain set (mandatory 
(core domains); important but optional domains; research agenda), and identified contextual 
factors.(6)  This adjustment adds another layer to the inner circle of the OMERACT Onion structure to 
allow specification of certain domains as mandatory in specific circumstances.  
 
Delphi Results 
The characteristics of those who participated in each round of the Delphi survey are presented in 
Table 1. In total 343 participants completed Round 1 of the Delphi survey, with 177 (52%) and 119 
(35%) completing Rounds 2 and 3 respectively (Figure 1). Table 1 illustrates that a cross-section of 
respondents were represented across the four stakeholder groups, from different continents, 
representing different clinical presentations or health professionals/research backgrounds.  
Table 2 presents the results of the Round 3 Delphi exercise presented by domains ďǇ ‘ƉĞŽƉůĞǁŝƚŚOA ?
ǀƐ ‘ŽƚŚĞƌƐƚĂŬĞŚŽůĚĞƌƐ ? groups. This illustrates those domains and items which reached the a priori 
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threshold for the core domains and for those which were eligible ĂƐ  ‘ŝŵƉŽƌƚĂŶƚ ďƵƚŽƉƚŝŽŶĂů ? ĂŶĚ
 ‘ƌĞƐĞĂƌĐŚĂŐĞŶĚĂ ?domains. These results are summarised in Figure 2.  
 
Phase 3 
The methods and results of Phase 1 and 2 were presented to delegates on Thursday 17th May 2018 at 
the OMERACT2018 plenary meeting in Terrigal, Australia. This meeting included clinicians, patients 
and patient representatives, researchers, industry representatives and methodologists. After being 
presented with this background, delegates were allocated to eight groups where they were asked to 
consider for 60 minutes the composition of the OMERACT core domain set based on the Delphi Round 
3 results as presented in Table 2. Each of the eight groups provided feedback after-which 102 
delegates voted on the mandatory and important but optional domains. There was 100% agreement 
that pain, physical function and over 90% agreement that quality of life and patient global assessment 
of target joint should be included as core domains. However the groups made the following 
recommendations: moving joint structure into a ƐĞƉĂƌĂƚĞ ĐĂƚĞŐŽƌǇ ŽĨ  ‘mandatory in specific 
ĐŝƌĐƵŵƐƚĂŶĐĞƐ ?ĂƐƚŚĞƌĞǁĂƐĐŽŶĐĞƌŶƚŚĂƚƚŚŝƐǁŽƵůĚŶŽƚďĞƌĞůĞǀĂŶƚĨŽƌall types of osteoarthritis trial 
interventions (i.e., non-structure modifiable interventions). The variability in Delphi score between 
patient and other stakeholder votes for a number of domains classified as important but optional (i.e. 
cognitive function and fatigue) was highlighted by the groups (Table 2), and the terminology used to 
describe activity and participation and direct costs.  
Following this, the Working Group members revised the preliminary OMERACT core domain set from 
the initial vote. A new rule was introduced to account for the wide variability in scores between the 
 ‘ƉĂƚŝĞŶƚ ? ĂŶĚ  ‘ŽƚŚĞƌ ƐƚĂŬĞŚŽůĚĞƌƐ ? ŐƌŽƵƉƐ ? tŚĞƌĞ ƚhere was a discrepancy of greater than 30% 
between the two groups, and where either group presented with less than 85% agreement that the 
domain was  ‘ĐƌŝƚŝĐĂů ?ƚŽŵĞĂƐƵƌĞ, then that would not be eligible for inclusion as an important but 
optional domain.  
The revised core domain set (Figure 2) was presented on Friday 18th May 2018 to the OMERACT2018 
plenary delegates for a final vote. This included 129 voting delegates. Since the included Core Domain 
ƉĂƐƐĞĚƚŚĞ ? ?A?ƚŚƌĞƐŚŽůĚ ?ƚŚĞǀŽƚĞƐĐŽƵŶƚĞĚĨƌŽŵƚŚĞƉƌĞǀŝŽƵƐĚĂǇ ?ƐǀŽƚŝŶŐwere brought forward. 
Therefore voting was cast on the composition of the Important but optional and research agenda 
domains. In trials investigating structure modifying interventions, joint structure should be assessed. 
The results of the vote on the core domain set are presented in Table 3. There was agreement by over 
the 70% threshold required by OMERACT to endorse the core domain set. 
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DISCUSSION 
 
This paper reports the agreed core domain set, developed using the OMERACT process, with 
international collaboration across a broad spectrum of key stakeholders involved in the care of people 
with hip and/or knee OA. This update has overcome previous limitations from the 1997 COS,(9) most 
notably: greater patient representation, internationalisation of pre-meeting views through an 
international Delphi, and structuring the findings in accordance to the OMERACT Filter 2.1.(7)   
Whilst the domains of pain, physical function and patient global assessment remain core domains, 
quality of life has been introduced through this updated core domain set. It is likely that further work 
through OMERACT will be needed to define domains encompassed within the broader concept of 
 ‘ƋƵĂůŝƚǇŽĨůŝĨĞ ? ?The project findings also include a number of new domains which are recommended 
(but not core) for clinical trials and which were not included in the 1997 core domain set.(9) These 
include: cognitive function, fatigue, sleep, impact of family/caregivers and psychosocial impact. This 
difference may correspond to the wider contribution of stakeholder views compared to Bellamy et 
Ăů ?Ɛ(9) COS, particularly the patient perspective. Nonetheless, it represents a change in domain 
selection towards a more diverse, biopsychosocial evaluation of clinical outcomes.  
This is the first OMERACT core domain set to include a contextual factor. The inclusion of adherence 
was considered important given the results of the Delphi survey where both patient and non-patient 
groups reported this as critical to include in trials with people for hip and knee OA. The Working Group 
considered this as a contextual factor as opposed to a domain as it is important to understand how 
adherent a participant is to an intervention, but it is, in most cases, not necessarily an outcome in itself 
(unless the trial is designed specifically to assess adherence). Through this means, adherence may be 
considered useful in the process evaluation of an interventional trial. The Working Group will consider 
how to expand on this list of contextual factors and determine the composition of this list. We hope 
the work of the OMERACT Contextual Factors Working Group will assist and guide the concepts and 
methodologies on how to determine what should be included in this list, to provide a consistent 
approach in identification and reporting. 
This study had a number of limitations. Firstly, as per OMERACT processes, the delegates at 
OMERACT2018 had the final consensus vote on the core domain set composition. Whilst this included 
129 individuals, the percentage of patients in the OMERACT delegate group was smaller than the 
percentage of patients in the Delphi study. However since delegates based their votes on the findings 
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from the Delphi survey, this approach was considered appropriate as any voting was therefore 
underpinned by the views of a wider and more diverse cohort. Secondly, members of the Working 
Group were required to formulate domains from items reported in the Delphi. Participants in the 
Delphi survey were required to vote on items rather than domains to provide more detailed views on 
specific aspects of domains e.g.  ‘pain intensity ? rather than just  ‘pain ?. However this may be viewed as 
introducing subjectivity in domain formulation. To negate this, the Working Group consisted of a wide 
variety of stakeholders including clinicians, researchers, methodologists and patients, to ensure that 
this process followed required OMERACT procedures and research or clinical perspective. Thirdly, 
both Phase 1 and Phase 2 included representation largely from three continents i.e. Europe, 
Australasia, North America. There was limited representation from Africa and central Asia. Whilst the 
social media strategy facilitated recruitment of some participants, most notably from Asia, the results 
from this core domain set may not necessarily represent global views. This is a recurrent limitation in 
COS development and one which requires further methodological consideration in future projects. 
Finally, whilst the Delphi survey gained arrange of responses internationally and from a number of 
different stakeholders, originally from 343 participants, the final Delphi round consisted of 119 
participants and therefore the Delphi only reflected the beliefs of those respondents rather than the 
343. 
The goal of the next 24 months will be to commence work on assessing instrument selection for 
mandatory domains from this agreed core domain set. These will be reviewed in accordance with 
Filter 2.1(7) with the ultimate aim of developing a new core outcome measurement set. In 
combination with this, the Working Group will promote the dissemination of the core domain set and 
subsequent COS through presentation of work to patients, healthcare professionals, researchers, 
regulatory authorities, funders and all individuals and groups involved in the care of people with OA. 
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Figure 1: Delphi Study Flow Diagram 
 
 
                   
Hyperlink opened for 4 weeks to allow potential respondents to 
complete Delphi Round 1 
ZĞƐƉŽŶĚĞŶƚ ?ƐĚĂƚĂĂŶĂůǇƐĞĚ 
(N=343) 
Non-respondents not 
followed-up again (N=83) 
End of Study Hyperlink opened for 2 weeks to allow potential respondents 
to complete Delphi Round 2 (N=343) 
Non-respondents not 
followed-up again (N=166) 
ZĞƐƉŽŶĚĞŶƚ ?ƐĚĂƚĂ
analysed (N=177) 
End of Study 
(N=166) 
 End of Study 
(N=119) 
 End of Study 
(N=58) 
Hyperlink opened for 2 weeks to allow potential 
respondents to complete Delphi Round 3 (N=177) 
 ZĞƐƉŽŶĚĞŶƚ ?Ɛdata 
analysed (N=119) 
Non-respondents not 
followed-up again (N=58) 
Patients, health professionals, researchers and people who work in industries 
allied to osteoarthritis (pharmaceutical/devices) 
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Figure 2: Endorsed OMERACT-OARSI core domain set for trials of people with hip and knee osteoarthritis.  
 
Research agenda domains x Clinician global assessment of target joint x Flare 
x Inflammation 
x Cognitive function 
x Fatigue 
x Impact on family/caregivers 
Important but optional 
domains 
x Participation 
x Psychosocial impact 
x Sleep 
x Costs 
Mandatory 
domains 
Mandatory in specific 
circumstances 
 
x Joint structure 
Mandatory in all trials x Pain x Physical function 
x Quality of life 
x Patient global assessment of target joint 
x Adverse effects (including death) 
    
 
 
 ŽŶƚĞǆƚƵĂů&ĂĐƚŽƌƐ 
/ŶĐůƵĚŝŶŐĚŚĞƌĞŶĐĞ 
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Table 1: Demographic characteristics of Delphi participants 
 Round 1 
(N; %) 
Round 2 
(N; %) 
Round 3 
(N; %) 
N 426 177 119 
Missing Data 83 (19.5) 0 (0.0) 0 (0.0) 
Stakeholders 
Patients with OA 217 (50.9) 67 (37.9) 42 (35.3) 
Health Professionals 65 (15.3) 39 (22.0) 29 (24.4) 
Researchers 131 (30.8) 65 (36.7) 42 (35.3) 
Industry 13 (3.0) 6 (3.4) 6 (5.0) 
Gender 
Male 133 (38.8) 65 (36.7) 46 (38.7) 
Female 210 (61.2) 112 (63.3) 73 (61.3) 
Joint affected by OA 
Knee 78 (22.7) 37 (20.9) 22 (18.5) 
Hip 24 (7.0) 15 (8.5) 10 (8.4) 
Hip and Knee 73 (21.3) 36 (20.3) 25 (21.0) 
Not declared 42 (12.2)  0 (0.0) 0 (0.0) 
Not affected by OA 126 (36.7) 89 (22.3) 62 (52.1) 
Health Professional Background 
Physiotherapist 61 (36.9) 36 (38.7) 27 (41.5) 
Rheumatologist 42 (27.3) 29 (31.2) 21 (32.3) 
Health Professional not listed 19 (12.3) 9 (9.7) 5 (7.7) 
Clinical Biomedical Scientist 6 (3.9) 3 (3.2) 3 (4.6) 
Orthopaedic Surgeon 8 (5.2) 3 (3.2) 2 (3.1) 
GP 6 (3.9) 3 (3.2) 1 (1.5) 
Occupational Therapist 3 (1.9) 2 (2.2) 0 (0.0) 
Holistic Therapist 1 (0.6) 0 (0.0) 0 (0.0) 
Clinical psychologist 2 (1.3) 2 (2.2) 1 (1.5) 
Nurse 4 (2.6) 4 (4.3) 3 (4.6) 
Chiropractor 2 (1.3) 2 (2.2) 2 (3.1) 
Country of Response 
Total number of countries represented 25 20 17 
UK 126 (36.7) 60 (33.9) 35 (29.4) 
Canada 38 (11.1) 21 (11.9) 14 (11.8) 
USA 36 (10.5) 17 (9.6) 13 (10.9) 
Australia 91 (22.8) 48 (27.1) 36 (30.3) 
Spain 6 (1.5) 3 (1.7) 2 (1.7) 
Switzerland 1 (0.3) 0 (0.0) 0 (0.0) 
Denmark 7 (1.8) 5 (2.8) 3 (2.5) 
The Netherlands 7 (1.8) 5 (2.8) 2 (1.7) 
Brazil 1 (0.3) 0 (0.0) 0 (0.0) 
Germany 5 (1.3) 2 (1.1) 2 (1.7) 
China 1 (0.3) 0 (0.0) 0 (0.0) 
New Zealand 1 (0.3) 0 (0.0) 0 (0.0) 
Belgium  2 (0.5) 1 (0.3) 1 (0.8) 
Iceland 2 (0.5) 1 (0.3) 1 (0.8) 
Norway 3 (0.8) 2 (1.1) 1 (0.8) 
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Japan 1 (0.3) 0 (0.0) 0 (0.0) 
Ireland 3 (0.8) 2 (1.1) 0 (0.0) 
Israel 1 (0.3) 0 (0.0) 0 (0.0) 
Italy 2 (0.5) 1 (0.6) 1 (0.8) 
Myanmar 1 (0.3) 1 (0.6) 0 (0.0) 
France 2 (0.5) 2 (1.1) 2 (1.7) 
India 1 (0.3) 1 (0.6) 1 (0.8) 
Sweden 3 (0.8) 3 (1.7) 3 (2.5) 
Russia 3 (0.8) 1 (0.6) 1 (0.8) 
Singapore 1 (0.3) 1 (0.6) 1 (0.8) 
GP  W general practitioner; N  W number of participants; OA  W osteoarthritis; UK  W United Kingdom; 
USA  W United States of America 
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Table 2: Formatted Delphi Round 3 results to illustrate the core areas, domains and items for the Round 3 Delphi results 
 Domain Item People 
with OA 
N=42 (%) 
Other 
Stakeholder 
Groups N=77 (%) 
Weighted 
average 
(1:1) (%) 
All 
stakeholders 
N=119 (%) 
MANDATORY       
Death Death Mortality/survival 76 72 74 78 
Life Impact Pain Pain (overall) 98 97 98 97 
Pain with activity 98 97 98 97 
Pain at rest 86 90 88 88 
Pain during the night 95 82 89 88 
Pain during the day 93 79 86 84 
Physical Function Mobility (such as walking) 100 96 98 98 
Leg function (patient reported) 98 79 89 86 
Personal activities of daily living 
(e.g. washing; dressing; toileting) 81 86 84 84 
Sports, Exercise and Physical 
Activity 74 70 72 76 
Quality of Life Quality of life 98 94 96 96 
Overall impact of OA on the 
person with OA (patient 
reported) 93 90 92 91 
Patient Global 
Assessment of Target 
Joint 
Overall improvement of the 
disease (patient reported) 81 82 82 82 
Adherence Adherence to a treatment or 
therapy 93 79 86 85 
Pathophysiological 
Manifestations 
Joint Structure Imaging (such as x-ray; MRI; 
ultrasound) reflecting changes in 
joint structure 71 40 56 63 
IMPORTANT BUT 
OPTIONAL 
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Life Impact Activity and 
Participation 
Role function (ability to do work 
or vocational activities) 79 68 74 71 
Psychosocial Impact 
 
Control over disease (self-efficacy 
including understanding of the 
condition) 83 61 72 69 
Perceived ability to cope with 
their OA (patient reported) 83 59 71 67 
Social withdrawal and isolation 79 43 61 55 
Sleep Sleep (including falling and 
staying asleep) 88 57 73 68 
Physical Function Joint control e.g. giving way 
(patient reported) 95 34 65 56 
Balance 90 25 58 49 
Muscle strength 86 47 67 62 
Joint range of motion 81 29 55 48 
Exercise tolerance and endurance 71 30 51 45 
Flare Flares of OA 71 47 59 56 
Patient perception of 
care 
Patient perception of clinician 
understanding of OA 95 28 62 55 
Clinician Assessment 
of OA Impact 
Overall impact of OA on the 
person with OA (clinician 
reported) 76 23 50 42 
Cognitive Function Cognitive or mental functioning 71 20 46 38 
Pathophysiological 
Manifestations 
Biomarkers Inflammation 74 31 53 46 
Abnormal central nerve changes 71 14 43 34 
Resource Use Direct Costs 
 
Healthcare utilisation (including 
costs and pain killer use; hospital 
admission and consultation with 
clinicians) 79 66 73 75 
Time to surgery (such as joint 
replacement) 83 42 63 61 
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RESEARCH 
AGENDA     
 
 
 Clinician Global 
Assessment of Target 
Joint 
Overall improvement of the 
disease (clinician reported) 67 21 44 37 
 Fatigue Fatigue 67 23 45 38 
 Impact on family, 
care givers 
Impact of disease on family; 
carers and friends 52 11 32 25 
 Cosmetic The appearance of the leg (e.g. 
leg shape and cosmetic 
appearance of lower limb) 14 4 9 8 
OA - osteoarthritis 
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Table 3: Summary of the voting scores for the core domain set from OMERACT2018. 
Domain Voting for 
Inclusion % 
Mandatory 
Pain 100 
Physical Function 100 
Quality of Life 90 
Patient Global Assessment of Target Joint 91 
Joint Structure 80 
Important But Optional Domains 
Participation 95 
Psychosocial Impact 71 
Sleep 81 
Costs 77 
Research Agenda 
Clinician Global Assessment of Target Joint  
 
82* 
Flare 
Inflammation 
Cognitive Function 
Fatigue 
Impact on Family/Caregiver 
 
* A vote was made for the Outer Circle collectively  
 
 
